

Dan Peer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1551201/dan-peer-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

14,378
citations

48
h-index

119
g-index

160
ext. papers

16,437
ext. citations

11.3
avg, IF

6.89
L-index

#	Paper	IF	Citations
140	Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer.. <i>Advanced Materials</i> , 2022 , e2106350	24	2
139	Delivery strategies of RNA therapeutics to leukocytes.. <i>Journal of Controlled Release</i> , 2022 , 342, 362-371	11.7	1
138	Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies 2022 , 117-146		
137	Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility.. <i>ACS Nano</i> , 2022 ,	16.7	3
136	Extrahepatic delivery of RNA to immune cells 2022 , 57-86		
135	Fe3O4 Nanoparticles and Paraffin Wax as Phase Change Materials Embedded in Polymer Matrixes for Temperature-Controlled Magnetic Hyperthermia. <i>ACS Applied Nano Materials</i> , 2021 , 4, 11187-11198	5.6	3
134	Principles for designing an optimal mRNA lipid nanoparticle vaccine. <i>Current Opinion in Biotechnology</i> , 2021 , 73, 329-336	11.4	19
133	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021 , 32, 012001	3.4	5
132	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. <i>Bioengineering and Translational Medicine</i> , 2021 , 6, e10213	14.8	38
131	Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. <i>Small</i> , 2021 , 17, e2100287	11	2
130	Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. <i>Nano Letters</i> , 2021 , 21, 4774-4779	11.5	8
129	Gene Silencing: Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer (Small 19/2021). <i>Small</i> , 2021 , 17, 2170086	11	
128	Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. <i>Nature Nanotechnology</i> , 2021 , 16, 1030-1038	28.7	12
127	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered Lipid Nanoparticles. <i>ACS Nano</i> , 2021 , 15, 9627-9637	16.7	32
126	Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo. <i>Molecular Therapy</i> , 2021 , 29, 2239-2252	11.7	12
125	Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles. <i>Journal of Controlled Release</i> , 2021 , 337, 378-389	11.7	6
124	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. <i>Pharmaceutics</i> , 2020 , 12,	6.4	8

123	RNA Delivery: A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes (Adv. Mater. 12/2020). <i>Advanced Materials</i> , 2020 , 32, 2070093	24	
122	Progress and challenges towards CRISPR/Cas clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2020 , 154-155, 176-186	18.5	14
121	Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. <i>ACS Nano</i> , 2020 , 14, 4774-4791	16.7	22
120	An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. <i>Nanoscale</i> , 2020 , 12, 1894-1903	7.7	10
119	Monoclonal antibody-based molecular imaging strategies and theranostic opportunities. <i>Theranostics</i> , 2020 , 10, 938-955	12.1	50
118	CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. <i>Science Advances</i> , 2020 , 6,	14.3	86
117	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. <i>Langmuir</i> , 2020 , 36, 13331-13341	4	6
116	Paving the Road for RNA Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2020 , 41, 755-775	13.2	72
115	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. <i>ACS Applied Nano Materials</i> , 2020 , 3, 10634-10645	5.6	26
114	Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. <i>Advanced Drug Delivery Reviews</i> , 2020 , 159, 364-376	18.5	21
113	A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. <i>Advanced Materials</i> , 2020 , 32, e1906128	24	75
112	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. <i>Biomaterials</i> , 2019 , 223, 119486	15.6	68
111	Therapeutic mRNA delivery to leukocytes. <i>Journal of Controlled Release</i> , 2019 , 305, 165-175	11.7	22
110	Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. <i>Methods in Molecular Biology</i> , 2019 , 1974, 151-159	1.4	3
109	Challenges in IBD Research: Novel Technologies. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, S24-S30	4.5	8
108	A tissue chamber chip for assessing nanoparticle mobility in the extravascular space. <i>Biomedical Microdevices</i> , 2019 , 21, 41	3.7	3
107	Personalized Tissue Implants: Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants (Adv. Mater. 1/2019). <i>Advanced Materials</i> , 2019 , 31, 1970007	24	3
106	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019 , 14, 629-635	28.7	92

105	Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. <i>Journal of Controlled Release</i> , 2019 , 313, 33-41	11.7	21
104	Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. <i>Advanced Materials</i> , 2019 , 31, e1803895	24	64
103	Engineering lymphocytes with RNAi. <i>Advanced Drug Delivery Reviews</i> , 2019 , 141, 55-66	18.5	18
102	Targeting central nervous system pathologies with nanomedicines. <i>Journal of Drug Targeting</i> , 2019 , 27, 542-554	5.4	12
101	Progress and challenges towards targeted delivery of cancer therapeutics. <i>Nature Communications</i> , 2018 , 9, 1410	17.4	976
100	A modular platform for targeted RNAi therapeutics. <i>Nature Nanotechnology</i> , 2018 , 13, 214-219	28.7	118
99	Hierarchical theranostic nanomedicine: MRI contrast agents as a physical vehicle anchor for high drug loading and triggered on-demand delivery. <i>Journal of Materials Chemistry B</i> , 2018 , 6, 1995-2003	7.3	10
98	Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles. <i>Nano Futures</i> , 2018 , 2, 045003	3.6	0
97	Gene Silencing in the Right Place at the Right Time. <i>Molecular Therapy</i> , 2018 , 26, 2539-2541	11.7	
96	Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. <i>Nature Communications</i> , 2018 , 9, 4493	17.4	106
95	Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. <i>Molecular Therapy</i> , 2017 , 25, 5-7	11.7	2
94	Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation. <i>ACS Nano</i> , 2017 , 11, 5195-5214	16.7	78
93	Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. <i>Molecular Therapy</i> , 2017 , 25, 1491-1500	11.7	33
92	Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. <i>Bioconjugate Chemistry</i> , 2017 , 28, 556-564	6.3	36
91	Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. <i>Seminars in Immunology</i> , 2017 , 34, 68-77	10.7	58
90	Next-Generation Lipids in RNA Interference Therapeutics. <i>ACS Nano</i> , 2017 , 11, 7572-7586	16.7	114
89	ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells. <i>Journal of Controlled Release</i> , 2017 , 257, 84-90	11.7	12
88	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. <i>Frontiers in Immunology</i> , 2017 , 8, 69	8.4	25

87	Platelet mimicry: The emperor's new clothes?. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016 , 12, 245-8	6	14
86	Zooming in on selectins in cancer. <i>Science Translational Medicine</i> , 2016 , 8, 345fs11	17.5	3
85	Targeting Cancer Using Nanocarriers. <i>Advances in Delivery Science and Technology</i> , 2016 , 131-155		1
84	Harnessing nanomedicine for therapeutic intervention in glioblastoma. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 1573-1582	8	29
83	RNA nanomedicines: the next generation drugs?. <i>Current Opinion in Biotechnology</i> , 2016 , 39, 28-34	11.4	28
82	Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality. <i>Bioconjugate Chemistry</i> , 2016 , 27, 855-62	6.3	54
81	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E16-22	11.5	57
80	Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 529-38	4.5	15
79	Future Outlook of Nanopharmacy: Challenges and Opportunities 2016 , 735-742		
78	Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine 2016 , 81-100		
77	Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. <i>Journal of Drug Targeting</i> , 2016 , 24, 780-786	5.4	21
76	Modulation of Immune Response Using Engineered Nanoparticle Surfaces. <i>Small</i> , 2016 , 12, 76-82	11	50
75	Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. <i>Journal of Controlled Release</i> , 2016 , 244, 149-156	11.7	15
74	The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection. <i>Infection and Immunity</i> , 2015 , 83, 2358-68	3.7	10
73	Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery. <i>Nanotechnology</i> , 2015 , 26, 115101	3.4	44
72	Nanomedicine as an emerging platform for metastatic lung cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 291-301	9.6	48
71	Dielectrophoretic characterization of cells in a stationary nanoliter droplet array with generated chemical gradients. <i>Biomedical Microdevices</i> , 2015 , 17, 91	3.7	2
70	Overcoming multidrug resistance with nanomedicines. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 223-388		51

69	Metastability in lipid based particles exhibits temporally deterministic and controllable behavior. <i>Scientific Reports</i> , 2015 , 5, 9481	4.9	12
68	Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. <i>ACS Nano</i> , 2015 , 9, 6706-16	16.7	106
67	Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. <i>Cancer Letters</i> , 2015 , 365, 57-67	9.9	15
66	Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. <i>Cancer Letters</i> , 2015 , 364, 59-69	9.9	83
65	Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. <i>ACS Nano</i> , 2015 , 9, 1581-91	16.7	118
64	Harnessing RNAi nanomedicine for precision therapy. <i>Molecular and Cellular Therapies</i> , 2014 , 2, 5		18
63	RNA interference-based therapeutics and diagnostics. <i>Drug Delivery and Translational Research</i> , 2014 , 4, 1-2	6.2	2
62	Nanoparticles for imaging, sensing, and therapeutic intervention. <i>ACS Nano</i> , 2014 , 8, 3107-22	16.7	211
61	Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. <i>Nanoscale</i> , 2014 , 6, 3742-52	7.7	48
60	Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine. <i>Cancer Letters</i> , 2014 , 354, 290-8	9.9	39
59	Precision nanomedicine in neurodegenerative diseases. <i>ACS Nano</i> , 2014 , 8, 1958-65	16.7	70
58	Featuring the special issue guest editor: Dan Peer, Ph.D. <i>Cancer Letters</i> , 2014 , 352, 1	9.9	4
57	Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. <i>ACS Nano</i> , 2014 , 8, 2183-95	16.7	74
56	Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing. <i>Journal of Controlled Release</i> , 2014 , 185, 109-20	11.7	39
55	Structural Characterization of the Drug Translocation Path of MRP1/ABCC1. <i>Israel Journal of Chemistry</i> , 2014 , 54, 1382-1393	3.4	5
54	Precision medicine--delivering the goods?. <i>Cancer Letters</i> , 2014 , 352, 2-3	9.9	24
53	Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. <i>Drug Delivery and Translational Research</i> , 2014 , 4, 96-103	6.2	43
52	Omics-based nanomedicine: the future of personalized oncology. <i>Cancer Letters</i> , 2014 , 352, 126-36	9.9	55

51 RNAi Nanomedicines toward Advancing Personalized Medicine **2014**, 59-79

50 Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. *Cancer Letters*, **2013**, 334, 221-7 9.9 60

49 Molecular and Cellular Therapies: New challenges and opportunities. *Molecular and Cellular Therapies*, **2013**, 1, 1 8

48 Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. *Journal of Controlled Release*, **2013**, 170, 295-305 11.7 21

47 eIF3c: a potential therapeutic target for cancer. *Cancer Letters*, **2013**, 336, 158-66 9.9 28

46 A daunting task: manipulating leukocyte function with RNAi. *Immunological Reviews*, **2013**, 253, 185-97 11.3 51

45 Harnessing nanomedicine for mucosal theranostics--a silver bullet at last?. *ACS Nano*, **2013**, 7, 2883-90 16.7 26

44 SNP detection in mRNA in living cells using allele specific FRET probes. *PLoS ONE*, **2013**, 8, e72389 3.7 15

43 Nanomedicines for Systemic Delivery of RNAi Therapeutics. *Advances in Delivery Science and Technology*, **2013**, 127-142

42 Altering the immune response with lipid-based nanoparticles. *Journal of Controlled Release*, **2012**, 161, 600-8 11.7 88

41 Liposomes and other assemblies as drugs and nano-drugs: from basic and translational research to the clinics. *Journal of Controlled Release*, **2012**, 160, 115-6 11.7 13

40 Polysaccharides as building blocks for nanotherapeutics. *Chemical Society Reviews*, **2012**, 41, 2623-40 58.5 257

39 Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivo. *Methods in Molecular Biology*, **2012**, 820, 105-16 1.4 4

38 Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. *Advanced Drug Delivery Reviews*, **2012**, 64, 1738-48 18.5 64

37 RNAi-based nanomedicines for targeted personalized therapy. *Advanced Drug Delivery Reviews*, **2012**, 64, 1508-21 18.5 125

36 Nanoparticle hydrophobicity dictates immune response. *Journal of the American Chemical Society*, **2012**, 134, 3965-7 16.4 342

35 RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. *PLoS ONE*, **2012**, 7, e43343 3.7 24

34 Liposomes, lipid biophysics, and sphingolipid research: from basic to translation research. *Chemistry and Physics of Lipids*, **2012**, 165, 363-4 3.7 11

33	Integrin-targeted nanoparticles for siRNA delivery. <i>Methods in Molecular Biology</i> , 2012 , 757, 497-507	1.4	9
32	Reshaping the future of nanopharmaceuticals: ad iudicium. <i>ACS Nano</i> , 2011 , 5, 8454-8	16.7	75
31	Antibody-mediated delivery of siRNAs for anti-HIV therapy. <i>Methods in Molecular Biology</i> , 2011 , 721, 339-53	1.4	16
30	Special delivery: targeted therapy with small RNAs. <i>Gene Therapy</i> , 2011 , 18, 1127-33	4	111
29	Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. <i>Journal of Controlled Release</i> , 2011 , 156, 231-8	11.7	171
28	Grand challenges in modulating the immune response with RNAi nanomedicines. <i>Nanomedicine</i> , 2011 , 6, 1771-85	5.6	30
27	Enhanced bioavailability of polyaromatic hydrocarbons in the form of mucin complexes. <i>Chemical Research in Toxicology</i> , 2011 , 24, 314-20	4	11
26	Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides. <i>ACS Medicinal Chemistry Letters</i> , 2011 , 2, 528-31	4.3	8
25	Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. <i>Biomaterials</i> , 2011 , 32, 4840-8	15.6	65
24	Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. <i>Nanotechnology</i> , 2011 , 22, 494016	3.4	22
23	RNAi nanomedicines: challenges and opportunities within the immune system. <i>Nanotechnology</i> , 2010 , 21, 232001	3.4	37
22	IKAP/HELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression. <i>Cell Adhesion and Migration</i> , 2010 , 4, 541-50	3.2	1
21	RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. <i>Molecular Therapy</i> , 2010 , 18, 370-6	11.7	175
20	The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. <i>Biomaterials</i> , 2010 , 31, 6867-75	15.6	280
19	Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. <i>Journal of Controlled Release</i> , 2010 , 148, 63-68	11.7	21
18	Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1458-66	4.5	21
17	Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. <i>Biomaterials</i> , 2010 , 31, 7106-14	15.6	123
16	Systemic siRNA delivery to leukocyte-implicated diseases. <i>Cell Cycle</i> , 2009 , 8, 853-9	4.7	30

15	Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. <i>Cancer Letters</i> , 2009 , 274, 118-25	9.9	40
14	Nanocarriers delivering RNAi to cancer cells: from challenge to cautious optimism. <i>Therapy: Open Access in Clinical Medicine</i> , 2009 , 6, 293-296		1
13	Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. <i>Science</i> , 2008 , 319, 627-30	33.3	428
12	Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins. <i>Blood</i> , 2008 , 112, 5007-15	2.2	24
11	Nanocarriers as an emerging platform for cancer therapy. <i>Nature Nanotechnology</i> , 2007 , 2, 751-60	28.7	6530
10	Corneal gene therapy. <i>Journal of Controlled Release</i> , 2007 , 124, 107-33	11.7	64
9	Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 4095-100	11.5	232
8	AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 13991-6	11.5	45
7	Fluoxetine and reversal of multidrug resistance. <i>Cancer Letters</i> , 2006 , 237, 180-7	9.9	54
6	Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. <i>Neoplasia</i> , 2004 , 6, 343-53	6.4	181
5	Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. <i>Cancer Research</i> , 2004 , 64, 7562-9	10.1	72
4	Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. <i>International Journal of Cancer</i> , 2004 , 108, 780-9	7.5	200
3	Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003 , 1612, 76-82	3.8	69
2	Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. <i>Archives of Biochemistry and Biophysics</i> , 2000 , 383, 185-90	4.1	37
1	Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids		1